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Abstract
Neurons of the nucleus basalis of Meynert (nbM) are vulnerable to Lewy body formation and neuronal loss, which is
thought to underlie cognitive dysfunction in Lewy body dementia (LBD). There is continued debate about whether Lewy
bodies exert a neurodegenerative effect by affecting mitochondria, or whether they represent a protective mechanism.
Therefore, the present study sought to determine whether the nbM is subject to mitochondrial dysfunctional in LBD and the
association of Lewy body formation with such changes. Post-mortem nbM tissue was stained for Complex I or IV and
quantitated relative to porin with immunofluorescence using confocal microscopy of individual cells from LBD (303 neurons,
8 cases), control (362 neurons, 8 cases) and asymptomatic incidental LBD (iLBD) cases (99 neurons, 2 cases). Additionally, α-
synuclein, tau and amyloid-β pathology were analysed using quantitative immunohistochemistry, and respiratory chain
markers were compared in cells with Lewy bodies (N = 134) and unaffected cells (N = 272). The expression of Complex I
normalised to mitochondrial mass was significantly lower in LBD compared to control and iLBD cases and this was unrelated
to local neuropathological burdens but trended toward a relationship with neuronal loss. Furthermore, Complex I expression
was higher in cells with Lewy bodies compared to adjacent cells without α-synuclein aggregates. These findings suggest
that Complex I deficits in the nbM occur in symptomatic LBD cases and may relate to neuronal loss, but that contrary to the
view that Lewy body formation underlies neuronal dysfunction and damage in LBD, Lewy bodies are associated with higher
Complex I expression than neurons without Lewy bodies. One could speculate that Lewy bodies may provide a mechanism
to encapsulate damaged mitochondria and/or α-synuclein oligomers, thus protecting neurons from their cytotoxic effects.
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Introduction
Lewy body dementia (LBD) is the second most common
form of late-life neurodegenerative dementia after Alzhei-
mer’s disease (AD), accounting for up to 20% of all cases
[15]. LBD is a collective term for dementia with Lewy bodies
(DLB) and Parkinson’s disease dementia (PDD), which are
clinically distinguished on the basis of the temporal onset of
symptoms, with cognitive symptoms preceding or occurring
concurrently with motor symptoms in DLB whereas motor
symptoms are a presenting feature of PDD [24]. DLB is
marked by particularly accelerated cognitive decline, even
compared to AD [16], yet there is an absence of therapies
that can offer anything but modest symptomatic treatment
[8]. Therefore, there is a pressing need to better understand
the mechanisms that underlie cognitive impairment in LBD
in the hope that these may contribute to the development of
disease-modifying therapies.
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The accumulation of the protein α-synuclein into
well-defined intracellular aggregates termed Lewy bodies
is the characteristic neuropathological feature of LBD
[27]. However, it should be noted that AD pathology,
consisting of hyper-phosphorylated tau and amyloid-β, is
typically a concomitant feature at levels intermediate be-
tween normal ageing and AD [24]. Although Lewy bod-
ies are necessary for a neuropathological diagnosis of
LBD, their relationship with clinical symptoms is contro-
versial, with studies showing conflicting findings relating
Lewy body burden to important clinical or pathological
variables [13, 14, 28, 43]. Despite the controversy sur-
rounding the role of Lewy bodies in neurodegeneration
in LBD, inhibition of α-synuclein aggregation into Lewy
bodies remains a major goal of candidate therapeutics
[17, 33, 46].
It is thought that the aggregation of α-synuclein from
an unstructured monomer into oligomeric and/or fibril-
lar aggregates characterised by β-sheet rich structures
mediates the cytotoxicity of α-synuclein through either a
loss of normal protein function or a gain of toxic func-
tion [27]. α-Synuclein is known to interact with mito-
chondria in vitro, where it inhibits Complex I of the
mitochondrial respiratory chain, and initiates a cascade
of oxidation events culminating in opening of the per-
meability transition pore, mitochondrial swelling and cell
death [20]. Consistent with mitochondrial interactions
driving cellular dysfunction and death in LBD, post-mor-
tem studies have consistently reported Complex I defi-
ciency in neurons in the substantia nigra, a region whose
degeneration is thought to underlie parkinsonian symp-
toms in LBD [34, 36]. Other studies have reported Com-
plex I deficiency in other brain regions, including those
without Lewy bodies [12].
The nucleus basalis of Meynert (nbM) is a diffuse nu-
cleus located in the basal forebrain. It is the largest of four
cell groups in the basal forebrain (Ch1 – Ch4), which pro-
vide cholinergic innervation to widespread brain regions
[25, 26], with the nbM (Ch4) providing cholinergic effer-
ents to the entire cerebral cortex [26]. Neuronal loss and
Lewy body pathology has long been recognized in the
nbM and is associated with cognitive impairment in a
number of clinical dementias, including Alzheimer’s dis-
ease and LBD [30, 44, 45]. The cells of the nbM are part
of a neuromodulatory network with long axons and dif-
fuse arborisations and are, thus, highly energy demanding
[39]. Given the high-energy demands of nbM cells, one
could speculate they may be susceptible to neurodegener-
ation secondary to mitochondrial dysfunction.
The present study sought to determine whether the
nbM is subject to reductions in complexes of the mito-
chondrial respiratory chain in LBD, and whether such
changes are associated with the burden of Lewy body
pathology. To better understand the relationship
between mitochondrial respiratory chain changes and α-
synuclein pathology we included participants with inci-
dental Lewy body disease (iLBD), individuals with Lewy
body pathology in the nbM but an absence of cognitive
or motor symptoms. We used the nbM as an exemplar
region as it is subject to severe Lewy body pathology and
cell-loss that is thought to underlie cognitive symptoms
in LBD. Unlike previous studies, which have relied on
light microscopic analysis of sections stained with single
antibodies, we have employed the novel approach of
quadruple immunofluorescence of individual cells with
confocal microscopy [18]. This approach enables respira-
tory chain markers to be normalised to the total mass of
mitochondria per cell, allowing precise determination of
specific deficits irrespective of differences in mitochon-
drial mass.
Methods
Case selection
Cases were obtained from Newcastle Brain Tissue Re-
source based on tissue availability (Table 1). We selected
a sub-set of LBD cases on the basis of a neuropatho-
logical diagnosis of LBD and an absence of concomitant
pathologies (Braak tau stage <IV, absence of significant
vascular pathology). Control cases were selected based
on documented evidence of intact cognition proximal to
death and an absence of significant age-associated path-
ology (Braak tau stage <II, absence of Lewy body and
vascular pathology). iLBD cases were only included if
they had clear evidence, from carer report or clinical
evaluation, of intact cognition immediately prior to
death and Lewy body pathology stage higher than 4, the
stage at which the nbM is affected [5].
Post-mortem tissue preparation
All brain tissue was obtained from Newcastle Brain Tis-
sue Resource (NBTR), a UK Human Tissue Authority–
approved research tissue depository, and ethical approval
was granted by Newcastle University ethics board and
the Joint Ethics Committee of Newcastle and North
Tyneside Health Authority (ref: 08/H0906/136). All
cases and controls had consented to the use of their
brain tissue for research purposes. At autopsy, the right
hemisphere was fixed in 10% formalin for 6 weeks prior
to paraffin wax embedding. Irrespective of clinical diag-
nosis, all brains underwent neuropathological assess-
ment [4, 5, 24, 40], and clinical and pathological data
were collated to establish a consensus clinico-
pathological diagnosis.
Neuropathology
Seven micrometers sections containing nbM tissue was
stained for ChAT, α-synuclein, amyloid-β and tau using
previously reported methods [10]. α-Synuclein
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immunohistochemistry employed the combined approach
of EDTA pH 8 and formic acid antigen retrieval and im-
munostaining with the KM51 antibody (1:250). Antigen
retrieval for amyloid-β utilised formic acid and the 4G8
antibody (1:10,000), and tau used citrate pH 6 and the
AT8 antibody (1:1000). Antibody immunopositivity was
visualised using Menarini MenaPath X-Cell Linked Plus
HRP detection systems, as per manufacturer’s instructions.
A region of interest was drawn around the neurons of the
nbM and immunopositivity determined using bespoke
thresholds, with percentage area immunoreactive calculated
using Image-Pro software (Media Cybernetics, Japan).
Immunofluorescent staining of brain tissue
To evaluate changes to the mitochondrial respiratory
chain in individual nbM cells, we employed a modified
version of a previous protocol [18]. Firstly, to determine
whether changes to mitochondrial respiratory chain sub-
units are found in the nbM in LBD, we co-stained nbM
sections with the cholinergic neuron marker ChAT (28),
a subunit of Complex I (NDUFB8; NADH dehydrogen-
ase [ubiquinone] 1 beta subcomplex unit 8), a subunit of
Complex IV (COX4; cytochrome oxidase subunit 4) and
a marker of mitochondrial mass (porin/VDAC1; Fig. 1).
Complex I and IV were evaluated as they have been pre-
viously been reported to be deficient in both mitochon-
drial disease [18] and Parkinson’s disease substantia
nigra [34, 36].
For our second experiment to compare expression of
mitochondria respiratory chain subunits in nbM neurons
with Lewy bodies, compared to those without Lewy bod-
ies, we replaced COX4 with the α-synuclein fibril
marker, Syn-F2 [41]. This antibody was chosen as its iso-
type is mouse IgG2a, which is identical to that of COX4,
thus enabling it to be easily multiplexed with the other
primary antibodies.
The immunofluorescence protocol involved deparaffini-
sation and rehydration of sections followed by antigen re-
trieval in 1mmol EDTA pH 8 in a pressure cooker for 40
min. Samples were blocked in 10% normal goat serum
suspended in tris-buffered saline with 1% Tween-20
(TBST) for 1 h at room temperature. Antibodies against
NDUFB8 (Abcam ab110242, 1:100), COX4 (Abcam
ab110261, 1:100), porin/VDAC1 (Abcam ab14734, 1:200)
and ChAT (Sigma HPA048547, 1:100) were suspended in
10% normal goat serum in TBST overnight at 4 °C. In the
second experiment, Syn-F2 (El-Agnaf laboratory, Qatar; 1:
1000) replaced COX4. After washing with TBST, second-
ary antibodies (Alexa Fluor 405-conjugated anti-rabbit
antibody, 1:100; Alexa Fluor 546-conjugated IgG1 anti-
mouse antibody, 1:100; Alexa Fluor 647-conjugated IgG2a
anti-mouse antibody, 1:100; Alexa Fluor 488- conjugated
IgG2b anti-mouse antibody, 1:100) were incubated for 1 h
at room temperature and washed off with TBST. Autoflu-
orescence was quenched by application of 3% Sudan Black
B for 10min at room temperature before slides were air-
dried and mounted in ProLong Gold antifade.
Table 1 Demographic data from the present cohort. “NFT Braak” refers to neurofibrillary tau pathology stage, “Thal phase” refers to
amyloid-β phase, and “LB Braak” refers to Lewy body pathology stage
Case ID Age Sex NFT Braak Thal phase LB Braak Number of cells analysed
Control 1 80 M I 1 0 46
Control 2 54 F II 5 0 50
Control 3 59 M I 3 0 49
Control 4 81 F I 3 0 36
Control 5 63 M I 3 0 49
Control 6 97 M II 2 0 35
Control 7 92 F I 2 0 50
Control 8 96 F I 2 0 47
iLBD 1 92 F II 5 5 49
iLBD 2 98 F II 2 5 50
LBD 1 90 M III 5 6 35
LBD 2 87 F II 5 6 30
LBD 3 76 M II 5 5 20
LBD 4 78 M III 1 6 51
LBD 5 74 M III 5 6 38
LBD 6 82 M I 1 6 30
LBD 7 92 M III 2 6 50
LBD 8 81 M III 4 6 49
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Confocal microscopy of single nbM neurons
Immunofluorescence was conducted using a Leica SP8
confocal microscope. The nbM was analysed at the level
of the amygdala based on the Newcastle Brain Tissue
Resource dissection protocol, and located based on its
location on the ventral aspect of the globus pallidus and
by the expression of ChAT in its distinctive large neu-
rons. All neurons were imaged at 63x oil immersion lens
and laser intensity settings were kept constant for every
case. The zoom and z stack functions were used to
image individual ChAT-positive neurons in three dimen-
sions across all evaluated channels. Z-stacked images
were obtained to avoid the introduction of bias by im-
aging of single two-dimensional points that would be ar-
bitrarily determined by the operator. Three-dimensional
images were compressed into a single two-dimensional
image and saved in greyscale to avoid bias in the analysis
of intensity by false colouring. We aimed to obtain 50
Fig. 1 Representative images of neurodegenerative pathologies in control (Control 5; a-c), iLBD (iLBD 1; d-f) and LBD (LBD 2; g-i) nbM. Only α-
synuclein burden differed across groups, where it was higher in iLBD and LBD compared to control. There was no significant difference in α-
synuclein levels between iLBD and LBD. *p < 0.05, **p < 0.01
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neurons per case or, if fewer neurons were present, every
cholinergic neuron present in the region of interest on
the section.
For densitometric analysis of the target proteins, ImageJ
software (U.S. National Institutes of Health, Bethesda,
MD, USA) was used and images from the four channels
were imported as an image sequence. The background
signal for each antibody was obtained by analysing stain-
ing intensity in single immunonegative regions proximal
to the region of interest. This was measured every five
cells, from which a mean background measure was calcu-
lated per slide, and subtracted from each measurement.
Cells were outlined manually based on ChAT and/or
porin immunostaining (porin was used when cells had low
levels of ChAT meaning cell outlines were less clear) and
mean optical densities (OD) from all channels were ob-
tained using the “analyse stack” function in ImageJ, giving
an optical density (OD) value for each channel in every
cell. Background corrected OD values for individual cells
were derived by subtracting the mean background signal
from each data point for each cell.
Analysis of respiratory chain marker expression in
individual neurons
Analysis and comparison of ChAT and porin were con-
ducted based on staining intensity irrespective of cell
size to ensure that optical density measures, which com-
bine intensity and area stained, would not bias analysis
in favour of larger cells and, thus, give lower expression
levels in atrophic cells. Such analysis could show de-
creases in ChAT secondary to cellular atrophy, not due
to reduced expression in cells.
Background-corrected OD values of NDUFB8 and
COX4 were normalised to background-correct porin
OD values and log-transformed to normalise data. Z-
scores per cell were determined relative to the normal
population (i.e. all ChAT-positive neurons in the control
group, N = 362) and compared on the group level by
pooling all cells within groups.
Comparison of complex I expression in cells with and
without Lewy bodies
We further investigated Complex I expression based on
its higher magnitude of deficiency in nbM neurons and its
relationship to α-synuclein aggregation in vitro [20, 23].
Therefore, we compared cells without α-synuclein aggre-
gates to those with either Lewy bodies, or to those with
diffuse aggregates, using the same methods as employed
to determine Complex I expression previously. In this
analysis, we evaluated all cells per nbM, which also gave
the total number of cholinergic neurons per LBD or iLBD
case. We also quantified the area occupied by the Lewy
body and subtracted this from each channel to determine
whether accumulated mitochondria within Lewy bodies
was artefactually altering expression. For this aspect of the
study, laser settings had to be optimised due to use of a
different batch of Sudan Black B that subtly altered stain-
ing intensity, thus the results from this part of the study
could not reliably be converted to z scores using control
data from the first part of the study, and thus ratios were
used instead.
Statistical analysis
All data were evaluated to determine whether they ad-
hered to a normal distribution using visual inspection of
Q-Q plots and Shapiro-Wilk tests, and heterogeneity of
variance was evaluated using Levene’s test of normality
of error variances. Complex I and IV expression from in-
dividual cells were analysed on the group level using a
mixed-effect model, with the individual cases included
as random effects. This analysis enabled comparison of
all cells between groups, whilst taking into account that
pooled observations from different cases cannot be con-
sidered independent observations. ANOVA or Kruskal-
Wallis tests followed by appropriate post-hoc tests were
used as appropriate, and parametric or non-parametric
correlational analyses used to evaluate relationships, as
appropriate. All analyses were performed using Graph-
Pad Prism 8 software except the mixed-effects model
which was performed in R.
Results
Demographics and neuropathology
There were no significant differences in the proportions
of men/women across groups (χ2 = 5.90, df = 2, p =
0.052); however, a trend was observed towards a higher
proportion of men in the LBD group, consistent with
previous studies showing LBD to be more common in
men [35], and the iLBD group was exclusively female.
No significant differences were observed in the age of in-
dividuals across groups (K-W χ2 = 3.362, df = 2, p =
0.186). All demographic data are summarised in Table 1.
Analysis of α-synuclein, amyloid-β and tau demon-
strated that only α-synuclein differed on the group level,
and this was in controls compared to LBD cases (p <
0.01) and iLBD cases (p < 0.05). There was no difference
between LBD and iLBD on any measure (Fig. 1).
Complex I is decreased relative to porin in LBD but not
iLBD
Immunofluorescent analysis of the expression of the
Complex I marker NDUFB8 and the Complex IV
marker COXIV were conducted relative to the mito-
chondrial membrane marker porin in single nbM neu-
rons to determine whether there were specific deficits in
respiratory chain complexes relative to total mitochon-
drial mass (Fig. 2). Initial analysis of porin expression
suggested it was significantly increased in iLBD and LBD
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cases compared to control (Supplementary Figure 1).
Pooled data of cells per case per experimental group
were evaluated in a mixed effects model to control for
the effect of the pooled cells being obtained from eight
individual cases. This analysis demonstrated that the
LBD group was significantly reduced in Complex I rela-
tive to porin compared to the control group (− 0.75, p =
0.049), whilst the iLBD group was not significantly dif-
ferent from the control group (0.18, p = 0.749). In con-
trast, Complex IV relative to porin was not significantly
different from control in LBD (− 0.40, p = 0.319) or iLBD
(0.11, p = 0.854; Fig. 2), once variations between individ-
uals were accounted for (Supplementary Figures 2 & 3).
Reductions in respiratory chain markers vary across LBD
cases
When individual neurons were stratified based on the de-
gree of their deficiency (based on standard deviations from
the control mean), LBD cases were highly variably affected
by Complex I reductions (Supplementary Figure 4).
We asked whether variation in the proportion of cells
with reduced Complex I expression (i.e. the proportion of
cholinergic neurons whose z score was more than one
standard deviation below the mean, as established from
the control z distribution) was associated with cell loss,
which is known to occur in the nbM in LBD and is
thought to underlie cognitive dysfunction (4). Quantifying
Fig. 2 Photomicrographs demonstrating reductions in mitochondrial respiratory chain expression in nbM cholinergic neurons in LBD.
Representative images demonstrating respiratory chain subunit expression in control (A.i.-A.iv.), iLBD (B.i.-B.iv.) and LBD (C.i.-C.iv.) cases. Scale
bars = 10 μm. Dot plots show group level analysis of z scores of Complex I/NDUFB8 and IV/COXIV normalised to porin. Bars are means and
standard deviation. *p < 0.05
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cell numbers in the nbM is difficult due to the lack of clear
borders and anatomical differences along the extent of the
nbM coupled with the difficulty in acquiring sections from
precisely the same coronal level. Nevertheless, as has been
conducted in previous studies [1], we counted the number
of cholinergic neurons in the area of the nbM on a single
7 μm section stained with ChAT, and observed a trend to-
wards a negative correlation between the number of cholin-
ergic neurons and proportion of cells with reductions in
Complex I (rs = − 0.576, p = 0.088; Supplementary Figure 5)
but not Complex IV (p = 0.204).
Complex I reductions are greater in cells without Lewy
bodies
We next aimed to determine the relationship between
Lewy body pathology and the observed reductions in
Complex I expression. Initial observation of sections
stained with the Syn-F2 antibody demonstrated two
broad classes of α-synuclein aggregate formation: well-
defined Lewy body-like structures and diffuse accumula-
tions (Fig. 2). Therefore, we compared Complex I
(NDUFB8) expression in cells without α-synuclein ag-
gregates to those with Lewy bodies or diffuse aggregates.
Due to a lack of suitable tissue, one case was excluded
from this analysis (LBD 8). The Complex I marker
NDUFB8 was normalised to porin and evaluated in cells
without any α-synuclein aggregates compared to cells
with diffuse accumulations and those with Lewy bodies.
Analysis across all cases with Lewy bodies in the nbM
demonstrated a significant main effect (K-W χ2 = 26.29,
p < 0.0001), with post-hoc analyses demonstrating higher
expression of Complex I in cells with Lewy bodies (N =
83; p < 0.001) and cells with diffuse α-synuclein aggre-
gates (N = 51; p < 0.01) compared to cells without any α-
synuclein aggregates (N = 272). However, there was no
significant difference between cells with Lewy bodies
and cells with diffuse α-synuclein aggregates (all data
summarised in Fig. 3). There was no difference in porin
levels between cells with and without α-synuclein aggre-
gates. When data was broken down into individual cases,
the same general trend of higher Complex I expression
in cells with Lewy bodies was observed within individual
cases (Supplementary Figure 6).
We also determined NDUFB8 expression relative to
porin in cells with and without α-synuclein aggregates
between groups with Lewy body pathology (i.e. LBD and
iLBD). LBD cases had a significant main effect (K-W
χ2 = 29.04, p < 0.0001), with post-hoc analyses demon-
strating higher expression of NDUFB8 relative to porin
in cells with Lewy bodies (N = 64; p < 0.001) and cells
with diffuse α-synuclein accumulation (N = 39; p <
0.001) compared to cells without any α-synuclein aggre-
gates (N = 187). iLBD cases also had a significant main
effect (K-W χ2 = 9.32, p < 0.01), with post-hoc analyses
demonstrating higher expression of NDUFB8 relative to
porin in cells with Lewy bodies (N = 19; p < 0.001) com-
pared to cells without any α-synuclein aggregates (N =
85). There was no significant difference in NDUFB8
relative to porin between cells with diffuse α-synuclein
accumulations (N = 12) and cells with or without Lewy
bodies. All data is summarised in Fig. 3.
We noted that porin and NDUFB8 were present
within Lewy bodies, whether viewed as flat 2D images or
following z stack. To ensure mitochondria within Lewy
bodies were not artefactually altering expression of mito-
chondrial proteins within cells with Lewy bodies we also
conducted this analysis having first subtracted the area
occupied by Lewy bodies from every channel. However,
this analysis demonstrated a similar trend, with a signifi-
cant main effect when data were pooled (K-W χ2 =
18.35, p < 0.001) and cells without α-synuclein contain-
ing significantly lower NDUFB8 relative to porin than
cells with Lewy bodies (p < 0.001) and cells with diffuse
α-synuclein (p < 0.05). Cells with Lewy bodies also had
higher levels of NDUFB8 relative to porin when only
cases with LBD (p < 0.001) or iLBD (p < 0.05) were ana-
lysed (Supplementary Figure 7).
Respiratory chain deficiencies are unrelated to
neurodegenerative pathology burden
Correlational analyses between α-synuclein percentage
area stained per case and the percentage of cells with re-
duced respiratory chain subunit expression (i.e. more
than one standard deviation below the control mean)
demonstrated a negative correlation between burden of
α-synuclein pathology and percentage of cells with re-
ductions in Complex I (rs = − 0.900, p = 0.002) and
Complex IV (rs = − 0.814, p = 0.011; Supplementary
Figure 8). These data suggest that lower levels of α-
synuclein pathology are associated with higher levels of
Complex I deficiency. We suspected these data may be
driven by the inherent bias of measures of percentage
area immunoreactive for α-synuclein towards the num-
ber of large Lewy bodies, thus biasing such measures to-
wards cases with higher numbers of cells. Therefore, we
correlated the percentage of total cells bearing Lewy
bodies with the percentage of cells with reduced levels
of respiratory chain subunit expression per case. This
analysis demonstrated no relationship between the per-
centage of cells bearing Lewy bodies and the percentage
of cells deficient in Complex I (p = 0.581) or Complex
IV (p = 0.643; Supplementary Figure 8). There was also
no relationship between percentage of cells bearing Lewy
bodies and cell density (p = 0.437; Supplementary Figure
9). There was no significant relationship between the
proportion of Complex I deficient neurons and tau (p =
0.233) or amyloid-β (p = 0.982).
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Discussion
The present study has demonstrated that the nbM, a
critical region for cortical cholinergic innervation, evi-
dences reductions in Complex I of the mitochondrial re-
spiratory chain in LBD that may relate to neuronal loss.
Notably, Complex I reductions were not observed in
asymptomatic iLBD cases, despite these cases manifest-
ing Lewy bodies of similar abundance to clinically symp-
tomatic cases of LBD in this region. Furthermore, cells
with Lewy bodies were found to have higher expression
levels of Complex I than cells without Lewy bodies, with
the most severe deficiencies observed in cells without
Lewy bodies. Taken together, these findings suggest that
the nbM is subject to reductions in Complex I expres-
sion in symptomatic LBD but that Lewy body formation
in neurons may be protective against these changes.
LBD are notable amongst neurodegenerative disorders as
neuronal loss is not as uniform as that observed in Alzhei-
mer’s disease [7, 9], nor is every region that manifests Lewy
bodies subject to cell loss [2, 6]. It has been suggested that
regions with particularly high energy demands would ren-
der some cellular populations particularly vulnerable to de-
generation, secondary to mitochondrial deficits [39].
Therefore, the present study reporting mitochondrial
Fig. 3 Photomicrographs demonstrating analysis of the Complex I marker NDUFB8 in nbM cholinergic neurons in LBD with or without the α-
synuclein marker Syn-F2. Representative images demonstrating a cell with a Lewy body (A.i.-A.v.) and a cell with diffuse α-synuclein accumulation
(B.i.-B.v.) with obvious Complex I/NDUFB8 expression, in contrast to a Complex I/NDUFB8 deficient cell with no α-synuclein immunoreactivity (C.i.-
C.v.). Scale bars = 10 μm. Analysis of Complex I/NDUFB8 normalised to porin in cells without α-synuclein aggregates, cells with diffuse α-synuclein
accumulations, and cells with Lewy bodies. Bars are means and standard deviation. **p < 0.01, ***p < 0.001
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respiratory chain deficits in the nbM, a region whose cells
have high energy demands and are also susceptible to Lewy
body pathology and significant cell loss [8], is consistent
with the hypothesis that regions with high energy demands
are vulnerable to neuronal loss and mitochondrial dysfunc-
tion in LBD.
Consistent with the hypothesis that regions with high
energy demands may be vulnerable to neurodegenera-
tion in the context of mitochondrial dysfunction in LBD,
we noted a statistically non-significant trend towards a
correlation between reductions in Complex I and cell
loss. However, it should be noted that our evaluation of
cell number, whilst necessary given the aforementioned
issues in quantifying cell density in the nbM, is less likely
to provide data as robust as stereological estimation
based on sampling of the entire structure [19]. Although
our estimates of cholinergic neuron number are similar
to those previously reported in the nbM in LBD with the
same method [1], it is impossible to exclude the possibil-
ity that differences in the area sampled across cases in-
fluenced cell density, and this could be contributing to
the trend towards a relationship between reductions in
Complex I and cell loss. Future studies are necessary to
better understand relationships between reductions in
Complex I and cell loss in LBD. Nevertheless, the under-
lying cause of reduced expression of respiratory chain
subunits in the nbM in LBD is not clear, but α-synuclein
has been demonstrated to interact with mitochondria
[22, 42], and reductions in Complex I expression have
been reported in the substantia nigra, where it was re-
lated to mtDNA deletions, and cortex in LBD post-mor-
tem tissue [12, 34, 36].
The aggregation of α-synuclein into Lewy bodies is
thought to be a central event in LBD, and the formation
of Lewy bodies is necessary for a neuropathological diag-
nosis of LBD [5, 24]. Previous studies have suggested
that the formation of Lewy bodies is cytotoxic to neu-
rons due to the propensity of α-synuclein aggregates to
sequester and accumulate critical cellular organelles,
particularly mitochondria [21, 32]. However, the present
study challenges the canonical view that Lewy bodies in-
duce mitochondrial dysfunction by demonstrating,
within nbM neurons, that Lewy bodies are associated
with higher levels of Complex I relative to total mito-
chondrial mass. The observation that Lewy bodies are
associated with higher expression of Complex I markers
conflicts with the results of previous studies that inter-
preted the presence of mitochondria within Lewy bodies
as a cytotoxic event [21, 32], but are consistent with
studies demonstrating Lewy body-bearing neurons are
less likely to manifest Complex I deficiency in the sub-
stantia nigra [12, 34]. Notably, we have extended previ-
ous findings in the substantia nigra by demonstrating
higher expression of Complex I in cells with Lewy bodies
in the nbM, suggesting this may be a common feature of
Lewy body bearing neurons.
In the present study, iLBD cases had no respiratory
chain dysfunction despite a comparable level of Lewy
body pathology in the nbM, suggesting that respiratory
chain dysfunction is a key distinction between symptom-
atic and asymptomatic cases. It is not clear why mito-
chondrial respiratory chain complexes would differ
between LBD and iLBD cases in the context of similar
local neurodegenerative pathology burdens. ChAT catal-
yses the production of acetylcholine from acetyl-CoA, a
key enzyme for mitochondrial energy production [38]
and, as ChAT expression is thought to be proportionate
to the rate of acetylcholine synthesis and substrate avail-
ability [38], one could speculate that the observed eleva-
tions in ChAT in the iLBD group reflect higher levels of
acetylcholine and acetyl-CoA. Elevations in acetylcholine
synthesis and acetyl-CoA expression in iLBD cases could
be a plausible explanation for preserved respiratory
chain expression and cognitive capacity in iLBD cases,
given that the abundance of acetyl-CoA reflects the gen-
eral energetic state of a cell [31] and acetylcholine has
critical roles in higher cognitive processes that are com-
promised in LBD [8]. However, it should be emphasised
that it is difficult to draw strong conclusions when the
iLBD cohort only comprised two patients. Limited num-
bers of iLBD cases were due to the rarity of cases with
widespread Lewy body pathology and an absence of clin-
ical features, and we acknowledge this as a limitation of
the present study.
The reasons for the association between the presence
of a Lewy body and greater cellular expression of Com-
plex I are unclear, but there are a number of plausible
explanations. It has been reported that Lewy bodies con-
tain dystrophic mitochondria [37] and, therefore, one
could speculate that Lewy bodies accumulate mitochon-
dria in response to mitophagy deficits [3], resulting in
less respiratory chain deficiencies in neurons harbouring
Lewy bodies. Mitophagy deficits may be a plausible ex-
planation given the significant increases in porin we ob-
served in LBD and iLBD cases though it is also possible
that the observed increase in porin expression reflects
oligomerisation into large channels that facilitate release
of pro-apoptotic proteins [38]. It is also possible that
Lewy bodies accumulate and compartmentalise more
toxic species of α-synuclein, such as putatively toxic
oligomers [11, 27]. In this regard, cells containing Lewy
bodies would be expected to have less respiratory chain
deficiencies than those containing more toxic species,
which may be too small to be visualised by light micros-
copy. Finally, it is possible that the generation of ATP by
mitochondria is necessary for the aggregation of α-
synuclein into Lewy bodies, and therefore cells with
greater expression of respiratory chain complexes are
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more likely to harbour Lewy bodies. However, given the
propensity of α-synuclein to aggregate in the absence of
ATP in vitro this seems less likely [29], but it may be the
case that formation of the structure of Lewy bodies,
reminiscent of an aggresome response, is dependent on
ATP. It should be noted that none of these explanations
are mutually exclusive.
It is important to emphasise that mitochondrial dys-
function is not the only proposed mechanism under-
lying cellular dysfunction in LBD, so it is possible
that Lewy bodies could be protective against reduc-
tions in markers of the mitochondrial respiratory
chain but cause cellular impairment through other
pathways, such as disruption of the microtubule net-
work or DNA damage [32]. It is also important to
note that the present findings or interpretation do
not necessarily diminish the central role ascribed to
α-synuclein in LBD. For example, it is possible that
increased expression of α-synuclein impairs the
autophagy-lysosomal system, inducing mitophagy im-
pairments thought to contribute to accumulation of
damaged mitochondria, and formation of Lewy bodies
in some cells to ameliorate the cytotoxic effect of this
accumulation. Nevertheless, further research is war-
ranted to determine how Lewy body accumulation
contributes to mitochondrial function and cellular
health in LBD.
In summary, the present study reports reduction in
Complex I of the mitochondrial respiratory chain in
nbM neurons in LBD compared to control and iLBD
cases, and this may be related to neuronal loss in this re-
gion. However, contrary to recent findings from in vitro
studies, cells with Lewy bodies are associated with higher
proportions of mitochondria with intact respiratory
chain subunits compared to neurons without Lewy bod-
ies. We speculate these findings suggest Lewy bodies
perform a protective function, perhaps by accumulating
more toxic species of α-synuclein and/or damaged mito-
chondria, thus protecting the cell from the deleterious
effects of accumulated cytotoxic components. However,
further studies are warranted to determine whether
Lewy bodies are a protective phenomenon, or whether
they exert cytotoxic effects through pathways other than
mitochondrial dysfunction.
Conclusion
The present study has demonstrated that reductions
in Complex I of the mitochondrial respiratory chain
are observed in the nbM of individuals with LBD,
and these may relate to the neuronal loss observed
in this region that is thought to underlie cognitive
deficits. Notably, such reductions were not observed
in individuals with iLBD, who had Lewy body
pathology but no clinical symptoms, suggesting
mitochondrial damage may relate more closely to
phenotype than the presence of absence of Lewy
bodies. Contrary to the view that Lewy bodies in-
duce cellular dysfunction underlying clinical symp-
tomatology in LBD, cells with Lewy bodies had less
dysfunctional mitochondria than proximal neurons
without Lewy bodies, suggesting Lewy bodies may
have a protective role in LBD.
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